• Increase font size
  • Default font size
  • Decrease font size

Stem cells show extraordinary potential to treat various cancers

Print E-mail
By Staff and Wire Reports   
Wednesday, 10 March 2010 11:22

Could latest results mean that IMUC is close to securing a partnership? ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.


CEO, Dr. Manish Singh told BioMedReports: “We believe this data, while received from animal studies, provides compelling evidence that cancer stem cells have extraordinary potential to treat various cancers. There were many promising markers,  including increased Gamma-Interferon levels in animals treated with CSCs, which suggest an increased immune response which is consistent with increased survival outcomes. We are excited about moving this into the clinic, as other companies have entered into partnerships with major pharmaceutical companies on less compelling data from animal studies."

According to the company, rats were either immunized with cancer stem cells (CSCs) from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that  that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. Furthermore, 30% of animals vaccinated against cancer stem cells demonstrated long term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.

“We are excited by the study’s results, as it represents a significant step forward in the continued development of our cancer stem cell based vaccines,” said Dr. Manish Singh , PhD., President and CEO of ImmunoCellular Therapeutics.  “The data further validates our research indicating that targeting CSCs has the potential to be a highly effective method of treating various cancers.”  The data also demonstrated increased Gamma-Interferon levels in animals treated with CSCs, indicating an increased immune response consistent with increase in survival further supporting the mechanism of action of this approach.

 





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 26 minutes ago Focus on Perifosine May Shift For AEterna Zenatis Investors: Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) is an oncol... http://t.co/2ZZQbrSG
about 2 hours ago NHS education reforms 'lack detail' http://t.co/YiUKVEsS
about 2 hours ago Molecular 'on-off' switch for Parkinson's disease discovered http://t.co/wZ1N0xhq
about 2 hours ago Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent http://t.co/CnJ8fKok
about 2 hours ago Roche's dalcetrapib failure fuels HDL debate, but CETP not done yet http://t.co/8H9JRnp9
about 2 hours ago Modest Gains Vanish As Stocks Reverse Lower http://t.co/AXlpfiAP
about 3 hours ago Reading: One More Reason the Market's Pullback is Not Over http://t.co/iSZ0oYUq
about 9 hours ago Novo’s Insulin Pill Quest is Holy Grail for Novo: Health http://t.co/1NixK9Mx

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified